ICMJE DISCLOSURE FORM

Date: Feb. 08, 2023

Your Name: Natalie K Heater

Manuscript Title: Treatment of Endocrine Resistant Metastatic Breast Cancer in the Era of Antibody

Drug Conjugates

Manuscript number (if known): ATM-23-314

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | Ti | Name all entities with whom you have this relationship or indicate none (add rows as needed) me frame: Since the initia | Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work |
|---|--|---|---|
| _ | All a second feedbar | V. N. | |
| 1 | All support for the | X_None | |
| | present manuscript (e.g., | | |
| | funding, provision of study materials, medical writing, article processing charges, etc.) | | |
| | | | |
| | | | |
| | | | |
| | No time limit for this | | |
| | item. | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | XNone | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | XNone | |
| | | | |
| | | | |

| 4 | Consulting fees | X_None | |
|------|---|--|--------|
| | | | |
| | | | |
| 5 | Payment or honoraria for | X_None | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X_None | |
| | testimony | | |
| | | | |
| 7 | Support for attending | XNone | |
| | meetings and/or travel | | |
| | | | |
| | | | |
| 8 | Patents planned, issued | X None | |
| | or pending | | |
| | | | |
| 9 | Participation on a Data | X None | |
| | Safety Monitoring Board | | |
| | or Advisory Board | | |
| 10 | Leadership or fiduciary | X None | |
| | role in other board, | | |
| | society, committee or | | |
| | advocacy group, paid or | | |
| | unpaid | | |
| 11 | Stock or stock options | XNone | |
| | • | | |
| | | | |
| 12 | Receipt of equipment, | X_None | |
| | materials, drugs, medical writing, gifts or other | | |
| | | | |
| | services | | |
| | | | |
| 13 | O thior imanification from | XNone | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Plea | se summarize the above | conflict of interest in the following box: | |
| | | | |
| No | one. | | |
| | | | |
| | | | |
| | | | |
| Plea | se place an "X" next to t | he following statement to indicate your agre | ement: |
| | p | and the second s | |

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Feb. 08, 2023

Your Name: Stephanie Franco

Manuscript Title: Treatment of Endocrine Resistant Metastatic Breast Cancer in the Era of Antibody

Drug Conjugates

Manuscript number (if known): ATM-23-314

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | Ti | Name all entities with whom you have this relationship or indicate none (add rows as needed) me frame: Since the initia | Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work |
|---|--|---|---|
| _ | All a second feedbar | V. N. | |
| 1 | All support for the | X_None | |
| | present manuscript (e.g., | | |
| | funding, provision of study materials, medical writing, article processing charges, etc.) | | |
| | | | |
| | | | |
| | | | |
| | No time limit for this | | |
| | item. | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | XNone | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | XNone | |
| | | | |
| | | | |

| 4 | Consulting fees | X_None | |
|------|---|--|--------|
| | | | |
| | | | |
| 5 | Payment or honoraria for | X_None | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X_None | |
| | testimony | | |
| | | | |
| 7 | Support for attending | XNone | |
| | meetings and/or travel | | |
| | | | |
| | | | |
| 8 | Patents planned, issued | X None | |
| | or pending | | |
| | | | |
| 9 | Participation on a Data | X None | |
| | Safety Monitoring Board | | |
| | or Advisory Board | | |
| 10 | Leadership or fiduciary | X None | |
| | role in other board, | | |
| | society, committee or | | |
| | advocacy group, paid or | | |
| | unpaid | | |
| 11 | Stock or stock options | XNone | |
| | • | | |
| | | | |
| 12 | Receipt of equipment, | X_None | |
| | materials, drugs, medical writing, gifts or other | | |
| | | | |
| | services | | |
| | | | |
| 13 | O thior imanification from | XNone | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Plea | se summarize the above | conflict of interest in the following box: | |
| | | | |
| No | one. | | |
| | | | |
| | | | |
| | | | |
| Plea | se place an "X" next to t | he following statement to indicate your agre | ement: |
| | p | and the second s | |

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Feb. 08, 2023 Your Name: Ami N Shah

Manuscript Title: Treatment of Endocrine Resistant Metastatic Breast Cancer in the Era of Antibody

Drug Conjugates

Manuscript number (if known): ATM-23-314

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | Ti | Name all entities with whom you have this relationship or indicate none (add rows as needed) me frame: Since the initia | Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work |
|---|--|--|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | X_None | |
| 3 | Royalties or licenses | XNone | |
| | | | |

| 4 | Consulting fees | X none | |
|----|--|-----------------------|-------------------------------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | X_None | |
| 6 | Payment for expert testimony | X_None | |
| 7 | Support for attending meetings and/or travel | XNone | |
| 8 | Patents planned, issued or pending | XNone | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | Gilead AstraZeneca | Advisory board Advisory board |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone | |
| 11 | Stock or stock options | XNone | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | XNone | |
| 13 | Other financial or non- financial interests | XNone | |

Please summarize the above conflict of interest in the following box:

The author participated in an advisory board for Gilead and for AstraZeneca and received payment for this service.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.